Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3139 - Novel therapy options for advanced & metastatic melanoma patients in EU5 countries result in a changing treatment pattern especially in BRAF mutant patients

Date

09 Oct 2016

Session

Poster display

Presenters

Mathias Bernhardt

Citation

Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377

Authors

M. Bernhardt, N. Schmidt, K. Acker

Author affiliations

  • Ims Global Oncology, IMS Health GmbH & Co. OHG, 60598 - Frankfurt/DE
More

Resources

Abstract 3139

Background

Real world data on treatment (TX) patterns in advanced and metastatic melanoma is of great value to demonstrate the use of novel therapy options. We provide an overview about the application of diagnostic marker testing and its implication on melanoma TX patterns in regard to novel targeting drugs that recently entered the market.

Methods

This study is based on IMS Oncology Analyzer™, a quarterly physician panel survey including anonymous retrospective patient (PT) data about disease and TX history, across all cancer types. Melanoma PTs treated within the year 2013 and 2015 in EU5 countries (France, Germany, Italy, Spain and UK) were analyzed.

Results

In 2013, 45.7% of adv. & met. melanoma PTs received chemotherapy (CT) in their 1st line, ∼45% received a targeted therapy either against members of the MAPK or the CTLA-4 pathway while 9% were treated with others drugs. In 2015, the percentage of CT PTs decreased to ∼10% while ∼85% of PTs received a targeted therapy including anti-PD1/PD-L1 TXs. Distribution of the PTs according their BRAF status shows that 2% of BRAF mutant (MUT) but ∼20% of wild type (WT) PTs are treated with CTs in their first line in 2015.

1st line TX regimens** 2013 2015
Base (sample PTs) All PTs (304) BRAF* WT (44.9%) BRAF* MUT (55.1%.) All PTs (481) BRAF* WT (39.6%) BRAF* MUT (60.4%)
MEK&BRAF 40.8% 1.7% 83.6% 48.4% 1.1% 84.5%
CTLA-4 4.3% 4.2% 4.1% 32.2% 66.9% 12.2%
PD1/PD-L1 - - - 4.2% 8.4% 1.5%
CT 45.7% 89.9% 9.6% 9.6% 19.1% 1.8%
Others 9.2% 4.2% 2.7% 5.6% 4.5% -

** PTs included in a clinical trial or don't receiving a systemic therapy were not considered *PTs with an unknown BRAF status or PTs awaiting test results were excluded Table 1: Stage III/IV melanoma 1st line TX landscape

Conclusions

This study indicates a switch towards targeted therapies accounting for more than 80% of 1st line melanoma therapies in 2015. Hereby, the information on the BRAF status is crucial and determines the TX decision in regard of the drug type. However, nearly 20% of BRAF WT PTs receive CTs in their 1st line irrespective of novel available therapy options. Further research is necessary to understand the missing uptake of novel TX options and the related clinical practice.

Clinical trial identification


Legal entity responsible for the study

IMS Health GmbH & Co. Ohg

Funding

IMS Health GmbH & Co. Ohg

Disclosure

M. Bernhardt, N. Schmidt, K. Acker: Employee of IMS Health

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings